10-K: Jazz Pharmaceuticals Details Share Capital Structure in SEC Filing

Jazz Pharmaceuticals provides a detailed overview of its share capital structure, including authorized and issued shares, dividend policies, and repurchase options in a recent SEC filing.

Summary

• Jazz Pharmaceuticals' authorized share capital is divided into 4,000,000 non-voting euro deferred shares and 300,000,000 ordinary shares.
• As of December 31, 2023, the company had 62,251,172 ordinary shares and 4,000,000 non-voting euro deferred shares issued and outstanding.
• The company's board is authorized to issue new shares for cash without shareholder approval for a period of five years from July 29, 2021.
• Irish law allows the company to opt out of statutory preemption rights, which was approved by shareholders on August 3, 2023, and is limited to 12,828,534 shares.
• Dividends can only be paid from distributable reserves, and the company's net assets must exceed its called-up share capital plus undistributable reserves.
• The company may repurchase its own shares, which are treated as redeemable shares under Irish law, and can be cancelled or held in treasury.
• Subsidiaries of the company may also purchase the company's shares, subject to shareholder authorization and certain conditions.
• The company's ordinary shares are listed on The NASDAQ Global Select Market under the trading symbol JAZZ.

Sentiment

Score: 7

Explanation: The document is factual and provides a clear overview of the company's share capital structure. There are no significant positive or negative sentiments expressed, but the information is important for investors.

Positives

• The company has the flexibility to issue new shares for cash without shareholder approval for a defined period.
• The company has the ability to repurchase its own shares, which can be used for various corporate purposes.
• The company has the ability to issue preferred shares with different rights and restrictions.
• The company has the ability to consolidate, divide, or subdivide its share capital.

Negatives

• The company's ability to pay dividends is restricted by Irish law and requires sufficient distributable reserves.
• The company's ability to repurchase shares is limited by Irish law and the company's constitution.
• The company's opt-out of statutory preemption rights is limited to a specific number of shares and expires on a specific date.

Risks

• The company's ability to issue new shares for cash without shareholder approval is limited to a specific period.
• The company's ability to repurchase shares is subject to certain conditions and limitations under Irish law.
• The company's opt-out of statutory preemption rights expires on a specific date and must be renewed.
• The company's ability to pay dividends is dependent on having sufficient distributable reserves and net assets.

Future Outlook

The document outlines the company's current share capital structure and policies, but does not provide specific forward-looking statements about future financial performance or share issuance plans.

Management Comments

• The company's board of directors is authorized to issue new ordinary or preferred shares for cash without shareholder approval for a period of five years from the date of the passing of the resolutions.
• The company's board of directors may declare dividends without shareholder approval to the extent they appear justified by profits lawfully available for distribution.

Industry Context

This document is a standard disclosure of share capital information for a publicly traded company, and the details provided are typical for companies listed on the NASDAQ. The specific details regarding Irish law and the company's constitution are unique to Jazz Pharmaceuticals.

Comparison to Industry Standards

• The share capital structure of Jazz Pharmaceuticals is similar to other publicly traded companies, with a mix of authorized and issued shares.
• The company's ability to issue new shares without shareholder approval is a common practice, but the specific timeframe and conditions are unique to Jazz Pharmaceuticals.
• The company's dividend policy is consistent with other companies that prioritize reinvestment and growth over immediate shareholder payouts.
• The company's share repurchase policy is also a common practice, but the specific terms and conditions are unique to Jazz Pharmaceuticals.
• The company's opt-out of statutory preemption rights is a common practice for Irish companies, but the specific terms and conditions are unique to Jazz Pharmaceuticals.

Stakeholder Impact

• Shareholders are provided with detailed information about the company's share capital structure and policies.
• Potential investors can use this information to assess the company's financial position and investment potential.

Next Steps

• The company's board may issue new shares for cash without shareholder approval until July 29, 2026.
• The company's current opt-out of statutory preemption rights expires on February 3, 2025, and must be renewed if the company wishes to continue this practice.

Key Dates

Keywords

share capital, ordinary shares, preferred shares, dividends, share repurchase, preemption rights, Irish law, NASDAQ, treasury shares